We're excited to announce the combination of Berkeley Lights and IsoPlexis, bringing together the Beacon and IsoSpark platforms to form the premier functional cell biology company. Visit Site

Q&A: Distributed Biological Processing Can Prevent Pandemics

News 09.11.20

Bioeconomy Powerhouse Berkeley Lights Nearly Triples Since IPO, Now Valued At $3.9 Billion

News 08.12.20

Health Care CEO Does 180 Zoom Calls In Three Days to Help Take Company Public

News 08.11.20

A Singular View of COVID-19

News 08.04.20

Samsung Biologics Launches S-CHOice Cell Line Expression Technology

News 07.22.20

Light-Based Chips Speed up Cell-Line Development for GSK

News 07.20.20

Berkeley Lights flies high with $178M IPO

News 07.17.20

Berkeley Lights, Inc. Rings the Opening Bell in Celebration of its IPO

News 06.17.20

As We Wait for a Vaccine, Scientists Work to Scale Up the Best COVID-19 Antibodies to Give New Patients

News 06.16.20

Get to IND Faster: Accelerated and High-Performance Cell-Line Development

News 06.15.20

Optofluidics Aids Cell Line Development for Antibody-Based Therapies

News 06.11.20

Antibody Therapies to Cure Coronavirus Now Under Human Trial Phase

News 05.21.20

Genomic, Synthetic Bio Platforms Power COVID-19 Antibody Discovery at Vanderbilt Lab

News 05.13.20

The Race Is On to Find the Holy Grail of Covid-19 Antibodies

News 05.11.20

Antibody Shots Could Give Short-Term Doses of COVID-19 Protection. Will They Arrive before a Vaccine?

News 05.08.20

The Hope behind Antibody Treatments as a Quick Coronavirus Fix

News 05.06.20

How to Prevent Another COVID-19? ‘Invest in Infrastructure’

News 05.05.20

Finding the Best Cells for Faster Drug Discovery